A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression is a phase 2 interventional study registered as NCT06365853 by AbbVie, with 108 participants enrolled, started 2024-07-29 and due to reach its primary completion in 2027-02. Interventions recorded: Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops. Conditions listed: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive. No results are recorded here; the registry entry is the source.